A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Trial Profile

A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Trastuzumab emtansine (Primary)
  • Indications Bladder cancer; Lung cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms Basket
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 09 Jun 2017 Planned number of patients changed from 72 to 100.
    • 02 Jun 2017 Primary end-point (Overall response rate (ORR) in patients with HER2 mutant lung cancers) has been met, according to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top